UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/07/25
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerGlobeNewsWire • 08/05/25
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025GlobeNewsWire • 07/29/25
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action LawsuitGlobeNewsWire • 07/28/25
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in UrologyGlobeNewsWire • 07/28/25
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action LawsuitGlobeNewsWire • 07/21/25
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the FirmGlobeNewsWire • 07/21/25
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerGlobeNewsWire • 07/21/25
UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action LawsuitGlobeNewsWire • 07/19/25
URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class ActionGlobeNewsWire • 07/17/25
UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd.GlobeNewsWire • 07/15/25
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmGlobeNewsWire • 07/11/25
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerGlobeNewsWire • 07/07/25
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNPRNewsWire • 07/02/25
URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for InformationGlobeNewsWire • 07/01/25
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitPRNewsWire • 06/30/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNPRNewsWire • 06/27/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNGlobeNewsWire • 06/23/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNGlobeNewsWire • 06/18/25
URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered LossesAccesswire • 06/16/25
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNGlobeNewsWire • 06/16/25
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGNAccesswire • 06/16/25